Sotagliflozin is a drug being developed to lower blood sugar levels in type 1 diabetes by increasing the amount of sugars excreted in the urine. It is taken once a day tablet in conjunction with insulin to prevent large rises and falls in blood sugar levels. This may be especially useful for people who cannot control their blood sugar levels with insulin alone. Sotagliflozin is currently in clinical trials which have shown that sotagliflozin has the potential to reduce and control blood sugar levels when taken with insulin.
Apabetalone is the first product developed to inhibit BET proteins. These BET proteins can control the activity of cells and make them produce proteins that cause inflammation. By inhibiting the BET proteins the production of inflammatory proteins is reduced. Apabetalone also increases production of high density lipoproteins which removes excess cholesterol, reducing the risk of cardiovascular disease. Apabetalone has the potential to affect multiple processes which contribute to cardiovascular disease, with the overall result of reducing the risk of a major adverse cardiac event in diabetic patients. If licensed, apabetalone may offer an additional preventive treatment option for major adverse cardiac events in patients with type 2 diabetes mellitus, high-risk a high risk of cardiovascular disease and low HDL.